%0 Journal Article
%T Experience With Vismodegib in the Treatment of Advanced Basal Cell Carcinoma at a Cancer Center.
%A Bernia E
%A Llombart B
%A Serra-Guillén C
%A Bancalari B
%A Nagore E
%A Requena C
%A Calomarde L
%A Diago A
%A Lavernia J
%A Traves V
%A Guillén C
%A Sanmartín O
%J Actas Dermosifiliogr (Engl Ed)
%V 109
%N 9
%D Nov 2018
%M 30055751
暂无%R 10.1016/j.ad.2018.06.003
%X <B>OBJECTIVE: </B>Vismodegib is the first selective Hedgehog inhibitor approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). In this article, we describe our experience with the use of this drug to treat advanced and/or multiple BCCs at a cancer center over 5 years.<BR><B>METHODS: </B>We analyzed the following variables: patient age and sex; tumor location, size, type, and characteristics; time since onset; primary or recurrent status; duration of treatment; response to treatment (complete, partial, stabilization, or absence of response); adverse effects; and recurrences.<BR><B>RESULTS: </B>We treated 22 patients, of whom 20 had locally advanced BCCs and 2 had metastatic BCCs with lymph node involvement. The treatment was administered over a mean of 11.8 months. Nine patients (41%) achieved complete response and 10 (45%) partial response. The disease was stabilized in 3 (14%). Two patients relapsed after a median of 21 months. The main adverse effects were dysgeusia, alopecia, and muscle cramps, all of which were mild. None of the patients developed squamous cell carcinoma in an area treated with vismodegib, although metatypical changes were observed after treatment.<BR><B>CONCLUSIONS: </B>With a response rate of 96%, vismodegib is a safe and effective treatment for locally advanced BCC. Adverse effects are generally mild but they need to be taken into account owing to their high frequency.